Read by QxMD icon Read

Onabotulinum toxin A

Riccardo Lombardo, Karl-Erik Andersson, Andrea Tubaro, Cosimo De Nunzio
BACKROUND: Endoscopic surgical treatment represents the gold standard in patients with lower urinary tract symptoms (LUTS) when medical treatment fails. In the past years there has been a growing interest in intra-prostatic injections which represent a minimally invasive alternative for those patients not suitable for surgery. Aim of our study is to systematically review all the available data on intra-prostatic injections for the treatment of LUTS patients with benign prostatic enlargement (BPE)...
October 3, 2018: Minerva Urologica e Nefrologica, the Italian Journal of Urology and Nephrology
Vikram M Narayan, Joseph J Pariser, Ronak A Gor, Jenna Katorski, Sean P Elliott
AIMS: Cerebral palsy (CP) is characterized by motor impairments as a result of brain injury during development. Patients can have neurogenic bladder dysfunction and are often unable to catheterize through their native urethra. Catheterizable channel (CC) creation can facilitate clean intermittent catheterization (CIC). We have observed that patients with large capacity, low-pressure bladders can develop de novo neurogenic detrusor overactivity (NDO) postoperatively. We sought to better characterize this finding...
September 24, 2018: Neurourology and Urodynamics
Giorgio Ivan Russo, Uros Milenkovic, Wayne Hellstrom, Laurence A Levine, David Ralph, Maarten Albersen
CONTEXT: Conservative therapies for Peyronie's disease (PD) aim to treat early-stage disease by improving clinical outcomes such as penile curvature, penile length erectile dysfunction, and pain. OBJECTIVE: To summarise the available evidence regarding injection and mechanical therapies for PD treatment. EVIDENCE ACQUISITION: An extensive search of Medline, Embase, and Scopus databases retrieved English-language articles up to 15 May 2018...
September 17, 2018: European Urology
Christine M Alvarez, James G Wright, Harpreet Chhina, Alyssa Howren, Peggy Law
BACKGROUND: Congenital idiopathic clubfoot is a condition that affects, on average, approximately 1 in 1,000 infants. One broadly adopted method of management, described by Ponseti, is the performance of a percutaneous complete tenotomy when hindfoot stall occurs. The use of onabotulinum toxin A (BTX-A) along with the manipulation and cast protocol described by Ponseti has been previously reported. Our goal was to compare the clinical outcomes between BTX-A and placebo injections into the gastrocnemius-soleus muscle at the time of hindfoot stall in infants with idiopathic clubfoot treated with the Ponseti method of manipulation and cast changes...
September 19, 2018: Journal of Bone and Joint Surgery. American Volume
Syed Imran Raza, Ashkan Heshmatzadeh Behzadi, Jon D Blumenfeld, Sarah K Girardi, Martin R Prince
Urinary incontinence due to neurogenic detrusor overactivity is common in patients with disorders of lower motor neurons controlling the bladder. Multiple sclerosis is a major cause of neurogenic detrusor overactivity, which negatively impacts quality of life. Bladder wall injection of onabotulinum toxin A can diminish spontaneous bladder contraction, urinary urgency, and urge incontinence. Herein we report a 61-year-old woman with multiple sclerosis and autosomal dominant polycystic kidney disease with bladder trabeculation developing after repeated injections of onabotulinum toxin A...
October 2018: Radiology Case Reports
J Ingham, R Angotti, M Lewis, A Goyal
INTRODUCTION: Botulinum toxin-A (BtA) has been used for refractory idiopathic overactive bladder (IOAB) in children. Data on the optimum dose success rates, duration of effect, complications and medium-term outcomes are limited. This study aims to analyse the authors' experience to provide medium-term results of BtA in symptomatic refractory patients. MATERIALS AND METHODS: Patients with refractory IOAB who were treated with BtA (Botox®) were retrospectively analysed...
August 16, 2018: Journal of Pediatric Urology
Irina Aschehoug, Daniel Fossum Bratbak, Erling Andreas Tronvik
OBJECTIVES: To investigate long-term outcomes in per-protocol chronic cluster headache patients (n = 7), 18 and 24 months after participation in "Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic cluster headache." METHODS: Data were collected prospectively through headache diaries, HIT-6, and open questionnaire forms at 18 and 24 months after the first treatment. Patients had access to repeated injections when needed...
September 14, 2018: Headache
A Doherty, D B Hennessey, J R Onggo, W Ranasinghe, J Gani
PURPOSE: One quarter of patients will not respond to initial intra-detrusor Botulinum toxin A (BTX) injections for detrusor overactivity. Alternative treatment options include long-term catheterization, sacral neuromodulation, urinary diversion or bladder augmentation. Some of these procedures are invasive. This review explores modifications to BTX delivery that can improve outcome. METHODS: A search of Medline, Embase and Cochrane Library to December 2017 was performed according to Preferred Reporting Items for Systematic Review and Metaanalysis (PRISMA) guidelines...
August 23, 2018: World Journal of Urology
Hiroyuki Todo, Hiroshi Yamasaki, Go Ogawa, Katsuya Nishida, Naonobu Futamura, Itaru Funakawa
INTRODUCTION: Camptocormia (severe bending of the spine) is a debilitating complication of Parkinson's disease (PD) without established treatment. Botulinum toxin (BT) may be beneficial, but data is scarce regarding the efficacy of administration of BT into the bilateral external oblique (EO) muscle for treatment of camptocormia in PD. METHODS: Six patients with PD and camptocormia, with flexion of the thoracic spine, were enrolled in the study. BT (75 or 90 units, onabotulinum toxin A) were injected into each EO bilaterally under sonographic guidance...
August 9, 2018: Neurology and Therapy
Dario Bertossi, Maurizio Cavallini, Pierfrancesco Cirillo, Salvatore Piero Fundarò, Sandro Quartucci, Chantal Sciuto, Davide Tonini, Gloria Trocchi, Massimo Signorini
BACKGROUND: The aesthetic treatment of facial and neck wrinkles with botulinum toxin is constantly increasing, thus making it necessary to collect procedures guidelines for the use of botulinum toxin in the treatment of wrinkles and/or cosmetic defects. METHODS: A group of nine Italian doctors, plastic and maxillo-facial surgeons, dermatologists and aesthetic physicians, experts in face and neck aesthetic treatments with onabotulinum toxin A, discussed on procedures used in their clinical practice...
August 9, 2018: Journal of Cosmetic Dermatology
Justin Houman, Ariel Moradzadeh, Devin N Patel, Kian Asanad, Jennifer T Anger, Karyn S Eilber
INTRODUCTION: Onabotulinum toxin A (Botox®) administered intravescially is an effective treatment for idiopathic detrusor overactivity, of which urinary tract infections (UTIs) are a common complication. The purpose of this study was to compare two prophylactic antibiotic regimens with the goal of decreasing UTI rates following intravesically administered Botox® injection. MATERIALS AND METHODS: A retrospective review of two groups of patients undergoing intravesically administered Botox® injections was performed-one with idiopathic and one with neurogenic detrusor overactivity...
August 3, 2018: International Urogynecology Journal
James M Weinberger, Justin Houman, Ashley T Caron, Devin N Patel, Avi S Baskin, A Lenore Ackerman, Karyn S Eilber, Jennifer T Anger
OBJECTIVE: To quantify the placebo effect of various pharmacologic modalities including neuromodulators, hormonal agents, and onabotulinum toxin A for female sexual dysfunction. DATA SOURCES: Using Meta-analyses Of Observational Studies in Epidemiology guidelines, we conducted a systematic review of PubMed, EMBASE,, and the Cochrane Review databases. METHODS OF STUDY SELECTION: Eleven search terms, "female sexual dysfunction" "treatment" in combination with "hypoactive sexual desire," "arousal disorder," "sexual pain disorder," "genitourinary syndrome of menopause," "orgasmic disorder," "vulvovaginal atrophy," "vaginismus," "vaginal atrophy," "vulvodynia," and "vestibulitis," were used...
August 2018: Obstetrics and Gynecology
Murat Uçar, Ahsen Karagözlü Akgül, Ayşe Parlak, Cem Yücel, Nizamettin Kılıç, Emin Balkan
OBJECTIVE: We aimed to evaluate the efficacy and safety of intravesical onabotulinum toxin A (onaBoNTA) injections for the treatment of children diagnosed with refractory overactive bladder (OAB) by using non-invasive methods. METHODS: A total of 31 pediatric patients with a mean age of 10.2 years received intravesical onaBoNTA injection at the dose of 10 U/kg (max: 200 U). Twenty-one patients who failed to respond to the first injection, received second injection 6 months after the first one...
August 2018: International Urology and Nephrology
Hans-Christoph Diener, Dagny Holle, Thomas Dresler, Charly Gaul
BACKGROUND: The frequent or regular use of analgesics and anti-migraine drugs can make headache more frequent and induce the transformation of episodic to chronic headache. Chronic headache due to medication overuse is defined as headache that is present on ≥ 15 days per month for at least three months in a patient who previously suffered from primary headaches, and who takes analgesics on ≥ 15 days per month or anti-migraine drugs (triptans or ergot alkaloids), opioid drugs, or combined analgesics on ≥ 10 days per month...
June 1, 2018: Deutsches Ärzteblatt International
Hannah Shoval, Esther Antelis, Andrew Hillman, Xiaofang Wei, Patricia Tan, Ruth Alejandro, Heakyung Kim
OBJECTIVE: To investigate the safety and efficacy of Onabotulinum Toxin-A (BTX-A) injection to the salivary glands under ultrasound guidance for the treatment of sialorrhea in patients with spinal muscular atrophy type I (SMA I). DESIGN: Prospective case series with four patients with SMA I who received BTX-A injection to parotid and submandibular glands for sialorrhea as part of clinical care. All four patients received validated surveys for measuring drooling, including objective measures of number of bib changes, and number of mouth wipes before injection and 4-6 weeks after injection...
June 18, 2018: American Journal of Physical Medicine & Rehabilitation
Souphiyeh Samizadeh, Koenraad De Boulle
Botulinum toxin A is produced by anaerobic spore-forming bacteria and is used for various therapeutic and cosmetic purposes. Botulinum toxin A injections are the most popular nonsurgical procedure worldwide. Despite an increased demand for botulinum toxin A injections, the clinical pharmacology and differences in formulation of commonly available products are poorly understood. The various products available in the market are unique and vary in terms of units, chemical properties, biological activities, and weight, and are therefore not interchangeable...
2018: Clinical, Cosmetic and Investigational Dermatology
Carlo Lovati, Luca Giani, Caterina Mariotti D Alessandro, Payam Tabaee Damavandi, Claudio Mariani, Leonardo Pantoni
No abstract text is available yet for this article.
June 2018: Neurological Sciences
Edgar L Leclaire, Jennifer Duong, Rachel M Wykes, Kevin E Miller, Tessa L Winterton, Milan Bimali
BACKGROUND: Intravesical injection with onabotulinum toxin A (BTX-A) injection can be performed in-office under local anesthesia. Rectally administered pain medication presents a potentially feasible and previously uninvestigated adjunct to office-based anesthesia protocols. OBJECTIVES: The primary aim of this study was to determine whether adding a belladonna and opiate (BO) suppository to standard lidocaine instillation resulted in reduction of bladder injection pain during BTX-A injection procedure...
June 11, 2018: American Journal of Obstetrics and Gynecology
Gregory Vurture, Benoit Peyronnet, Andrew Feigin, Milton C Biagioni, Rebecca Gilbert, Nirit Rosenblum, Steven Frucht, Alessandro Di Rocco, Victor W Nitti, Benjamin M Brucker
OBJECTIVE: To assess the safety and efficacy of intradetrusor onabotulinum toxin A injections for the treatment of overactive bladder (OAB) in patients with Parkinson's disease (PD). METHODS: All PD patients who underwent intradetrusor injections of onabotulinum toxin A (BoNT-A) for storage symptoms between 2010 and 2017 were included in a retrospective study. A 100 U dose of BoNT-A (Botox®, Allergan Irvine, CA) was used for the first injection in all patients...
May 16, 2018: Neurourology and Urodynamics
Benoit Peyronnet, Benjamin M Brucker, Martin C Michel
CONTEXT: Pharmacological treatment is a cornerstone in the management of patients with lower urinary tract symptoms (LUTS). OBJECTIVE: To review emerging evidence in the medical treatment of LUTS. EVIDENCE ACQUISITION: An Embase/Pubmed-based literature search was conducted in December 2017, screening for randomized controlled trials (RCTs), prospective and retrospective series, animal model studies, and reviews on medical treatment of LUTS...
January 2018: European Urology Focus
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"